LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: COVID-19 impact and predictive factors for mortality in cancer patients

    Sanz Garcia, E. / Peinado, P. / Moreno, I. / Dorta, M. / Alvarez, B. / Alvarez Gallego, R. / Madurga, R. / Rodriguez Pascual, J. / Ugidos, L. / Muñoz, C. / Garcia-Rico, E. / Cubillo, A.

    Annals of Oncology

    Abstract: Background: SARS-CoV-2 is a novel coronavirus that has been responsible for the largest pandemic in the last century: COVID-19 This disease has widely affected Spain with a high lethality in ancient patients (pts) and with comorbidities Oncological pts ... ...

    Abstract Background: SARS-CoV-2 is a novel coronavirus that has been responsible for the largest pandemic in the last century: COVID-19 This disease has widely affected Spain with a high lethality in ancient patients (pts) and with comorbidities Oncological pts were not an exception Methods: We evaluated the association between COVID-19 mortality and clinical/laboratory/radiological parameters in cancer pts from March to April 2020 at our institution Past medical history and COVID-19-related parameters (symptoms, laboratory/x-ray findings and treatments) were retrospectively collected Univariate analysis (UA) has been done using Fisher exact and U-Mann-Withney test for qualitative and quantitative variables, respectively Multivariant analysis (MA) has been done using logistic regression Results: Forty three hospitalized pts were diagnosed with COVID-19;30 pts (69 8%) were symptomatic on admission and 13 pts (30 2%) were hospital-acquired cases Median age was 68 8 ± 7 8 years Most part of the pts had gastrointestinal (GI) (13;30 2%), thoracic (Tx) (12;27 9%) and breast (6;14%) cancer A higher prevalence of Tx tumours compared to our new pts prevalence is observed (9%) Fever was the most common symptom (27;62 8%) and bilateral pneumonia was observed in 24 pts (55 8%) SARS-Co-V-2 PCR was positive in 34 pts (79 1%) Hydroxychloroquine was administered in 35 pts (81 4%), steroids and antiretrovirals in 19 pts (44 1%) and tocilizumab in 12 pts (27 9%) Mortality rate due to COVID-19 was 30 23% (13 pts) and 8 pts could resume oncological treatment Hypertension (HTA) and previous daily steroids given during last month before admission;as well as performance status, fever, Curb-65, SOFA score and D-Dimer (DD) at admission were associated with COVID-19 mortality in UA Similarly, high flow oxygen requirements during hospitalization and DD at 72 hours are predictors of mortality HTA [OR: 8 3 (1-5-70 1)], steroids [OR: 10 7 (1 3 – 143 8)] and fever [OR: 0 09 (0 01 – 0 55)]were also associated in MA Conclusions: COVID-19 showed a relative higher incidence in pts with Tx and GI tumours Some clinical and laboratory parameters were found to be predictive factors for mortality as previously reported in non-cancer pts Further investigations with larger number of pts are needed Legal entity responsible for the study: HM Hospitales Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #806039
    Database COVID19

    Kategorien

  2. Article ; Online: 1760P COVID-19 severe pneumonia in cancer patients

    Peinado, P. / Sanz Garcia, E. / Moreno, I. / Dorta, M. / Alvarez, B. / Alvarez Gallego, R. / Madurga, R. / Ugidos, L. / Rodriguez Pascual, J. / Muñoz, C. / Garcia-Rico, E. / Cubillo, A.

    Annals of Oncology

    Impact and predictive factors

    2020  Volume 31, Page(s) S1024

    Keywords Oncology ; Hematology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2020.08.1824
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: 1749P COVID-19 impact and predictive factors for mortality in cancer patients

    Sanz Garcia, E. / Peinado, P. / Moreno, I. / Dorta, M. / Alvarez, B. / Alvarez Gallego, R. / Madurga, R. / Rodriguez Pascual, J. / Ugidos, L. / Muñoz, C. / Garcia-Rico, E. / Cubillo, A.

    Annals of Oncology

    2020  Volume 31, Page(s) S1021

    Keywords Oncology ; Hematology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2020.08.1813
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Therapeutic management of epithelial ovarian cancer during pregnancy.

    Minig, L / Otaño, L / Diaz-Padilla, I / Alvarez Gallego, R / Patrono, M G / Valero de Bernabé, J

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

    2012  Volume 15, Issue 4, Page(s) 259–264

    Abstract: Epithelial ovarian cancer (EOC) during pregnancy is a rare condition. The diagnosis and treatment strategies are therefore not well defined. The evidence is scarce and limited to small case reports or case series. In this review we describe the safety, ... ...

    Abstract Epithelial ovarian cancer (EOC) during pregnancy is a rare condition. The diagnosis and treatment strategies are therefore not well defined. The evidence is scarce and limited to small case reports or case series. In this review we describe the safety, utility and limitations of each diagnostic tool and surgical procedure in pregnant women with ovarian cancer. We also discuss the role of chemotherapy for ovarian cancer during pregnancy. Finally, we delineate different strategies of treatment according to the stage of the disease at diagnosis and gestational age. Due to the complexity of the management of EOC during pregnancy, patients should be referred to specialized centers. Gestational age at diagnosis, the initial surgical procedure, disease stage and patient's preferences are the key factors in the decision-making process to establish the best treatment strategy for each individual case.
    MeSH term(s) Carcinoma, Ovarian Epithelial ; Disease Progression ; Female ; Humans ; Medical Oncology/legislation & jurisprudence ; Medical Oncology/methods ; Medical Oncology/trends ; Models, Biological ; Neoplasms, Glandular and Epithelial/pathology ; Neoplasms, Glandular and Epithelial/therapy ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Practice Guidelines as Topic ; Pregnancy ; Pregnancy Complications, Neoplastic/therapy
    Language English
    Publishing date 2012-11-21
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 2397359-6
    ISSN 1699-3055 ; 1699-048X
    ISSN (online) 1699-3055
    ISSN 1699-048X
    DOI 10.1007/s12094-012-0963-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.

    Cubillo, Antonio / Álvarez-Gallego, Rafael / Muñoz, Manuel / Pond, Gregory / Perea, Sofía / Sánchez, Gema / Martin, María / Rodríguez-Pascual, Jesús / Garralda, Elena / Vega, Estela / de Vicente, Emilio / Quijano, Yolanda / Muñoz, César / Ugidos, Lisardo / Toledo, Rodrigo A / Hidalgo, Manuel

    American journal of clinical oncology

    2018  Volume 42, Issue 1, Page(s) 56–59

    Abstract: Background: Previous studies have shown that metastatic colorectal carcinoma (mCRC) patients treated with bevacizumab, experience variation in the plasma levels of angiogenesis growth factors and related cytokines, called angiogenic switch (AS). The aim ...

    Abstract Background: Previous studies have shown that metastatic colorectal carcinoma (mCRC) patients treated with bevacizumab, experience variation in the plasma levels of angiogenesis growth factors and related cytokines, called angiogenic switch (AS). The aim of the present study was to analyze the relationship between AS and the clinical response during standard chemotherapy-bevacizumab treatment.
    Patients and methods: Patients with Eastern Cooperative Oncology Group 0-1 mCRC were eligible. Patients received treatment with standard dose capecitabine plus either oxaliplatin or irinotecan and bevacizumab for 6 cycles. Initial treatment was followed by maintenance therapy with bevacizumab plus capecitabine until progression. Plasma levels of angiogenic-related cytokines (hepatocyte growth factor, placental growth factor, macrophage chemoattractant protein-3, MM-9, eotaxin, basic fibroblast growth factor, and interleukin 18) were prospectively analyzed at baseline and every 8 weeks. Progression-free survival (PFS) was calculated using the Kaplan-Meier method.
    Results: A total of 71 patients were enrolled. AS was observed in 45 patients (63.4%), 28 of whom experienced AS at the first evaluation after treatment start. Disease control, which includes partial/complete response and stable disease, was seen in 96% of AS patients (43/45), but only in 15/26 (58%) for the remaining patients without evidence of AS (P<0.001). The median PFS of AS patients was 11.4 months (95% confidence interval, 8.6-15.8) versus 8.3 months for patients without AS (95% confidence interval, 5.6-16.4; P=0.04).
    Conclusions: Chemotherapy plus Bevacizumab combination in mCRC patients results in dynamic changes in plasma cytokines, which is associated with better disease control and longer PFS. These new findings support continuing studying AS as a potential marker of angiogenesis inhibitor effectiveness.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Cytokines/blood ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Disease-Free Survival ; Female ; Fluorouracil/analogs & derivatives ; Fluorouracil/therapeutic use ; Humans ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome
    Chemical Substances Angiogenesis Inhibitors ; Cytokines ; Deoxycytidine (0W860991D6) ; Bevacizumab (2S9ZZM9Q9V) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2018-07-05
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 604536-4
    ISSN 1537-453X ; 0277-3732
    ISSN (online) 1537-453X
    ISSN 0277-3732
    DOI 10.1097/COC.0000000000000474
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top